RnRMarketResearch.com adds "Alzheimer’s Disease – Pipeline Review, H2 2014" to its store. This report provides an overview of the Alzheimer’s Disease’s therapeutic pipeline.
Dallas, TX -- (SBWIRE) -- 11/13/2014 -- The report "Alzheimer’s Disease – Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Alzheimer’s Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer’s Disease and special features on late-stage and discontinued projects. Alzheimer's infection (AD), otherwise called Alzheimer sickness, is the most widely recognized manifestation of dementia. Regularly, Alzheimer's illness is diagnosed in individuals in excess of 65 years old, despite the fact that the less-common early-onset Alzheimer's can happen in much more youthful individuals.
Complete Report is Available
Companies Involved in Alzheimer's infection Development are: AB Science, AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Accera, Inc., Acelot, Inc., Acumen Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc., Addex Therapeutics Ltd, Advanced Cell Technology, Inc., Affichem, AFFiRiS AG, Alector LLC, ALSP, Inc., AlzeCure Discovery AB, Alzhyme Pty Ltd, Alzinova AB, AlzProtect SAS, Amarantus Bioscience Holdings, Inc., Amgen Inc., Anavex Life Sciences Corp., Angita B.V., Apodemus AB, Araclon Biotech, S.L., Archer Pharmaceuticals, Inc., ArmaGen Technologies, Inc., Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Ausio Pharmaceuticals, LLC, Avergen Ltd, Avineuro Pharmaceuticals, Inc., Axerion Therapeutics, Inc., Axon Neuroscience SE, Axxam SpA, Azevan Pharmaceuticals, Inc., BioArctic Neuroscience AB, biOasis Technologies Inc., Biogen Idec Inc., Biomar Microbial Technologies Bionature E.A. Ltd., Bionure Farma, S.L., Biotie Therapies Corp., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, BSIM2, CalAsia Pharmaceuticals, Inc., Cardax Pharmaceuticals, Inc., Celon Pharma Sp. z o.o., CHA Bio & Diostech Co., Ltd., Chase Pharmaceuticals Corporation Clera Inc., Cognition Therapeutics, Inc., Cognosci, Inc., CoLucid Pharmaceuticals, Inc., CoMentis, Inc., Cortica Neurosciences, Inc., Critical Outcome Technologies Inc., CrystalGenomics, Inc., D-Pharm Ltd., Daewoong Pharmaceutical Co., Ltd., Delenex Therapeutics AG, DermaXon, LLC, Domain Therapeutics SA, Echo Pharmaceuticals B.V., Eisai Co., Ltd., Eli Lilly and Company
EncephRx, Inc., EndoCeutics, Inc., Epigen Biosciences, Inc., Eucalyptus Ltd., Euroscreen S.A., Evotec AG, F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., Galantos Pharma GmbH, Genentech, Inc., Genervon Biopharmaceuticals, LLC, GlaxoSmithKline plc, GliaCure Inc., Grifols, S.A., H. Lundbeck A/S, High Point Pharmaceuticals, LLC, Humanetics Corporation, Ichor Medical Systems, Inc., Icure Pharmaceutical Inc., IMMD Inc., Immunome Inc., ImStar Therapeutics Inc., Inovio Pharmaceuticals, Inc., Intellect Neurosciences, Inc., Intra-Cellular Therapies, Inc., Io Therapeutics, Inc., Iproteos S.L., Janssen Pharmaceuticals, Inc., Jeil Pharmaceutical Co., Ltd., Johnson & Johnson, K-Stemcell Co., Ltd., Kareus Therapeutics, SA, KineMed, Inc., Kyowa Hakko, Kirin Co., Ltd., Laila Pharmaceuticals Pvt. Ltd., Lead Discovery Center GmbH, Les Laboratoires Servier SAS, Lipopharma Therapeutics SL, Living Cell Technologies Limited, Lupin Limited, ManRos Therapeutics, MedDay.
Order a Purchase copy
Reasons to buy the report "Alzheimer’s Disease – Pipeline Review, H2 2014": Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies. Identify and understand important and diverse types of therapeutics under development for Rabies. Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Inquire for Discount
(This is a premium report priced at US$2500 for a single user License.)
Table of Contents
Alzheimer's Disease Overview
Alzheimer's Disease - Therapeutics under Development by Companies
Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes
Alzheimer's Disease - Pipeline Products Glance
Alzheimer's Disease - Products under Development by Companies
Alzheimer's Disease - Products under Investigation by Universities/Institutes
Alzheimer's Disease - Companies Involved in Therapeutics Development
Alzheimer's Disease - Therapeutics Assessment
Alzheimer's Disease - Recent Pipeline Updates
Alzheimer's Disease - Dormant Projects
Alzheimer's Disease - Discontinued Products
Alzheimer's Disease - Product Development Milestones
Explore more reports on Pharmaceuticals industry